Pilot Study of a Raltegravir Based NRTI Sparing Regimen

Conditions

Acquired Immune Deficiency Syndrome | AIDS | HIV Infections | Human Immunodeficiency Virus

What is the purpose of this trial?

This pilot study will provide data on the safety and efficacy of the combination of Raltegravir (RAL) 400mg BID + Atazanavir (ATV) 300 mg BID in Antiretroviral (ARV)-experienced subjects that have a suppressed HIV viral load on a Ritonavir (RTV) boosted Protease Inhibitor (PI) based regimen who are then switched to a regimen of RAL 400mg BID +ATV 300mg BID.



Participation Guidelines

Age:
18 Years and older
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Bristol-Myers Squibb
Merck Sharp & Dohme Corp.
Yale University
Dates:
December 2008
Last Updated:
February 28, 2012
Study HIC#:
0812004547

Clinicaltrials.gov ID: NCT00814879